Kanjinti 420 mg (Trastuzumab KIT) 420 MG

KANJINTI 420 MG is a pharmaceutical product containing trastuzumab, used for targeted therapy. This intravenous kit is manufactured by Amgen Canada Inc. and is designed for specific medical applications.

Strength

420 MG

Manufacturer / TM Owner

AMGEN CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

KANJINTI 420 MG, containing trastuzumab, is primarily used in the treatment of certain types of cancer. It is often prescribed for conditions where targeted therapy is beneficial, such as in the management of HER2-positive breast cancer. Patients may wonder, 'What is KANJINTI 420 MG used for?' and the answer lies in its role as a monoclonal antibody that targets specific proteins involved in cancer cell growth.

Side Effects

Common effects of KANJINTI 420 MG may include infusion reactions, fatigue, and nausea. Some patients might experience fever, chills, or weakness. These effects can vary from person to person and are not exhaustive. Always consult a healthcare provider for personalized information.

Precautions & Warnings

KANJINTI 420 MG should be handled with care and administered by a healthcare professional. It is important to follow the prescribed guidelines for storage and administration. Patients with known allergies to trastuzumab or any of the kit's components should inform their healthcare provider before use.

Avoid Interactions

KANJINTI 420 MG may interact with other medications, including those that affect the immune system. It is crucial to inform your healthcare provider about all medications you are taking to avoid potential interactions. Always follow the advice of a healthcare professional regarding the use of this product.

Frequently Asked Questions

KANJINTI 420 MG is used in the treatment of certain types of cancer, particularly HER2-positive breast cancer.

KANJINTI 420 MG is administered intravenously by a healthcare professional.

Common effects may include infusion reactions, fatigue, and nausea.

It is important to consult a healthcare provider to avoid potential interactions with other medications.

KANJINTI 420 MG is manufactured by Amgen Canada Inc.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.